Medications for Venous Thromboembolism

4 results

  • Fragmin (dalteparin sodium)

    (Dalteparin Sodium)
    Pfizer Laboratories Div Pfizer Inc
    Usage: FRAGMIN is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, deep vein thrombosis (DVT) prevention in surgical and at-risk patients, extended treatment of symptomatic VTE in cancer patients, and VTE treatment in pediatric patients. It is not for acute VTE treatment.

  • Pradaxa

    (dabigatran etexilate mesylate)
    Boehringer Ingelheim Pharmaceuticals Inc.
    Usage: PRADAXA Capsules are indicated for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism in adults, prophylaxis post-hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to less than 18 years.

  • Xarelto

    (rivaroxaban)
    Janssen Pharmaceuticals, Inc.
    Usage: XARELTO is indicated for reducing stroke and systemic embolism in nonvalvular atrial fibrillation, treating deep vein thrombosis and pulmonary embolism, preventing recurrence of these conditions, and offering prophylaxis in post-surgery and hospitalized patients. It also reduces major cardiovascular events in patients with coronary artery disease and peripheral artery disease.

  • Xarelto (rivaroxaban)

    (rivaroxaban)
    Cardinal Health 107, LLC
    Usage: XARELTO is indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing DVT post-surgery, and pediatric thromboprophylaxis. It also reduces major cardiovascular events in coronary artery disease and thrombotic events in peripheral artery disease patients.